Expert Guidance on Treating Cyclic Vomiting and Cannabis Hyperemesis Episodes at Home and in the ER

A 2025 clinical narrative review in Neurogastroenterology & Motility synthesizes current pharmacologic and non-pharmacologic abortive strategies for cyclic vomiting syndrome and cannabinoid hyperemesis syndrome, noting that the evidence base remains limited and largely driven by expert opinion rather than randomized trial data.

Why This Matters

Cyclic vomiting syndrome and cannabinoid hyperemesis syndrome cause episodic, disabling nausea and vomiting that can lead to serious complications including acute kidney injury, cardiac arrhythmia, and Mallory-Weiss tears. Many patients endure years of misdiagnosis, repeated emergency department visits, and fragmented care. As cannabis use rises and diagnostic awareness grows, front-line clinicians increasingly encounter these patients without clear, consolidated guidance on how to abort acute episodes. A practical synthesis of available treatment options, even one grounded primarily in expert consensus, fills an immediate gap in clinical decision-making.

Clinical Summary

Cyclic vomiting syndrome and cannabinoid hyperemesis syndrome share a pattern of recurrent, stereotyped episodes of intense nausea and vomiting separated by symptom-free intervals, yet their underlying triggers and optimal management may differ in ways that remain poorly defined. Published in Neurogastroenterology & Motility in 2025, this narrative review by gastroenterology specialists and a patient-advocacy representative synthesizes existing literature and clinical experience to outline abortive treatment strategies across two settings: home and the emergency department. The mechanistic rationale for early intervention rests on the observation that most CVS patients experience a recognizable prodrome, with symptom onset occurring a median of approximately 50 minutes before the transition to full emesis, creating a window during which pharmacologic intervention may prevent or shorten episodes.

The review catalogs multiple drug classes used for acute episode abortion, including triptans, antiemetics, anxiolytics, NK-1 receptor antagonists, antipsychotics, NSAIDs, and sedatives, and provides tabulated dosing, side-effect profiles, and clinical considerations for each. Non-pharmacologic adjuncts such as sensory reduction, hot water bathing, and topical capsaicin receive attention, particularly for CHS. However, the authors are transparent that no rigorous head-to-head trials exist to guide selection among these agents, and efficacy rankings are drawn from observational studies, case series, and expert experience. They note that whether CVS and CHS require fundamentally different abortive approaches remains an open question, and they call for randomized controlled trials and comparative effectiveness research before firm clinical recommendations can be made.

Dr. Caplan’s Take

This review does something genuinely useful: it gathers scattered clinical wisdom about aborting CVS and CHS episodes into one practical reference. Patients with these conditions suffer enormously, and many have told me about emergency department visits marked by skepticism, undertreated pain, and inconsistent protocols. The gap here is not in the clinical logic, which is sound, but in the evidence underpinning it. When a patient asks me whether a triptan or an antiemetic will work better for their prodrome, the honest answer is that we do not yet have the trial data to say with confidence.

In practice, I work with these patients to build individualized home treatment plans that prioritize early intervention during the prodromal window. I discuss each medication option frankly, including its evidence basis and side-effect profile, and I encourage patients to keep episode logs so we can refine their regimen over time. For patients with frequent ED visits, I help develop written care plans they can carry with them, because consistent and compassionate emergency treatment should not depend on which physician is on duty that night.

Clinical Perspective

This review sits at the beginning of what should be a more rigorous research arc for CVS and CHS abortive therapy. It confirms the clinical consensus that early, prodrome-targeted intervention is the most effective strategy and provides a useful medication reference, but it does not resolve any comparative efficacy questions. The evidence does not yet support recommending one agent class over another with confidence. Patient-facing conversations should acknowledge this uncertainty while emphasizing the importance of having a plan in place, particularly one that includes home-based options to reduce reliance on emergency care.

Several pharmacologic considerations deserve clinician attention. Triptans carry cardiovascular contraindications relevant to patients with coronary artery disease or uncontrolled hypertension. Benzodiazepines, while useful for the anxiety component that often accompanies and worsens episodes, carry dependence risk with repeated use. The role of cannabis itself is complicated: some adults with CVS report symptomatic benefit, but escalation risk is real, and cannabis use in pediatric and young adult populations is contraindicated. One immediately actionable step is to ensure every patient with a confirmed CVS or CHS diagnosis leaves the clinic with a written, individualized abortive protocol covering both home and ED settings.

Study at a Glance

Study Type

Narrative clinical review

Population

Pediatric and adult patients with cyclic vomiting syndrome or cannabinoid hyperemesis syndrome

Intervention

Multiple pharmacologic and non-pharmacologic abortive strategies (triptans, antiemetics, anxiolytics, NK-1 antagonists, antipsychotics, NSAIDs, capsaicin, hot water bathing)

Comparator

None; no head-to-head comparisons or control groups

Primary Outcomes

Episode abortion or mitigation; clinical guidance for home and emergency department settings

Sample Size

Not applicable (no original data collection)

Journal

Neurogastroenterology & Motility

Year

2025 (accepted August 2024)

DOI

10.1111/nmo.14901

Funding Source

Not reported

What Kind of Evidence Is This

This is a narrative clinical review, not a systematic review or meta-analysis. It sits in the lower tier of the evidence hierarchy, synthesizing existing literature and expert opinion without a reproducible search strategy, predefined inclusion criteria, or quantitative evidence synthesis. The single most important inference constraint this imposes is that readers cannot assess completeness or bias in the evidence selected, and the recommendations carry the weight of expert consensus rather than guideline-level certainty.

How This Fits With the Broader Literature

The review aligns with and extends prior consensus statements, including the 2019 NASPGHAN consensus guidelines on CVS in children and the Rome IV criteria framework, by providing more granular pharmacologic guidance specifically focused on episode abortion rather than prophylaxis. It echoes findings from Venkatesan and colleagues regarding triptan efficacy in the prodromal window and from Dezieck and colleagues regarding topical capsaicin in CHS. However, it does not meaningfully advance the evidence base beyond these prior works, because it generates no new data and does not systematically grade the existing literature. Its primary contribution is consolidation and clinical accessibility rather than scientific novelty.

Common Misreadings

The most likely overinterpretation is reading this review’s structured medication tables and dosing recommendations as evidence-based treatment guidelines. They are not. The organized format and clinical specificity may create an impression of established efficacy rankings, but the authors themselves acknowledge that comparative data do not exist. A clinician who selects one agent over another based solely on this review’s relative efficacy summary should understand that those rankings reflect aggregated clinical experience, not controlled trial results. Similarly, the observation that effective abortive therapy may reduce episode frequency by lowering anticipatory anxiety is a plausible hypothesis, not a demonstrated causal relationship.

Bottom Line

This narrative review provides a practical, consolidated reference for clinicians managing acute CVS and CHS episodes, emphasizing early prodromal intervention and individualized treatment plans. It does not establish comparative efficacy among agents or generate new evidence. Its recommendations are expert-informed and clinically reasonable but await validation through randomized controlled trials. For now, the most defensible clinical action is ensuring every diagnosed patient has a written, personalized abortive protocol for both home and emergency settings.

References

1. Abortive and acute treatment of cyclic vomiting syndrome and cannabinoid hyperemesis syndrome. Neurogastroenterology & Motility. 2025. DOI: 10.1111/nmo.14901.
2. Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. Neurogastroenterology & Motility. 2019;31(Suppl 2):e13604.
3. Dezieck L, Hafez Z, Conicella A, et al. Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: a case series. Clinical Toxicology. 2017;55(8):908-913.
4. Li BUK, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. Journal of Pediatric Gastroenterology and Nutrition. 2008;47(3):379-393.